Baseline characteristics of participants
| Mean (SD) | Median (IQR) | Minimum–maximum | |
|---|---|---|---|
| Age at enrolment | |||
| Honevo N=68 | 57.7 (13.7) | 58.2 (46.7–68.3) | 23.4–86.5 |
| Control N=69 | 58.9 (15.9) | 60.1 (49.0–68.6) | 18.2–90.1 |
| All N=137 | 58.3 (14.8) | 58.9 (48.1–68.6) | 18.2–90.1 |
| Age at diagnosis | |||
| Honevo N=64 | 42.2 (15.4) | 40 (30–51.5) | 19–80 |
| Control N=67 | 43.6 (15.4) | 43 (35–55) | 10–79 |
| All N=131 | 42.9 (15.4) | 41 (32–54) | 10–80 |
| Honevo N (%) N=68 | Control N (%) N=69 | |
|---|---|---|
| Female | 32 (47.1) | 36 (52.2) |
| History of oral antibiotics | 13 (19.1) | 13 (18.8) |
| History of topical therapy | 24 (35.3) | 20 (29.0) |
| History of topical steroid | 6 (8.8) | 6 (8.7) |
| European | 64 (94.1) | 68 (98.6) |
| Maori | 4 (5.9) | 0 (0) |
| Asian | 0 (0) | 1 (1.5) |